← ANALYST RATINGS · TIPRANKS
Myriad Genetics (MYGN): analyst forecast and price target
Analyst consensus
Hold1 Buy1 Hold2 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $4.42, the highest $8.00, the lowest $2.00. The average is +11.2% from the last price of $3.98.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $4.50+12.5% | Hold | +13.1% | Reiterated | 16.10.26on TipRanks 01:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $4.00 → $4.50+12.5% | Hold | +13.1% | Reiterated | 16.10.26on TipRanks 01:05 | — | |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $4.00 → $4.50+12.5% | Hold | +13.1% | Reiterated | 13.10.26on TipRanks 08:46 | −2.8%next day +2.8% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $4.50 → $4.00−11.1% | Hold | +0.5% | Reiterated | 08.10.26on TipRanks Oct 7 22:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.50 → $4.00−11.1% | Hold | +0.5% | Upgrade | 08.10.26on TipRanks Oct 7 22:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $4.50 → $4.00−11.1% | Sell | +0.5% | Reiterated | 08.10.26on TipRanks Oct 7 22:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $4.50 → $4.00−11.1% | Hold | +0.5% | Reiterated | 08.10.26on TipRanks Oct 7 22:05 | — | |
| William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% | Craig-Hallum | $4.00 → $8.00+100.0% | Buy | +101.0% | Reiterated | 02.10.26on TipRanks 09:20 | +11.1%next day +0.2% · 5 days −6.2% | ↗ |
| Unknown Analyst | UBS | $6.00 → $3.60−40.0% | Hold | −9.5% | Initiated | 08.09.26on TipRanks Sep 14 09:30 | +0.2%next day +0.8% · 5 days +23.1% | ↗ |
| David Westenberg★★★★★★★★★★#602 · hits 56% · avg +17.3% | Piper Sandler | $8.50 → $2.00−76.5% | Sell | −49.7% | Downgrade | 01.09.26on TipRanks 05:15 | −0.6%next day +1.1% · 5 days +0.2% | ↗ |
| Unknown Analyst | Jefferies | $2.50 | Sell | −37.2% | Reiterated | 21.08.26on TipRanks 23:05 | −4.4%next day +4.3% · 5 days +5.1% | ↗ |
| Mason Carrico★★★★★★★★★★#10833 · hits 38% · avg −4.7% | Stephens | $3.00 | Hold | −24.6% | Assigned | 18.08.26on TipRanks 06:40 | −5.2%next day +10.9% · 5 days +11.4% | ↗ |
| Unknown Analyst | Guggenheim | — | Hold | — | Reiterated | 03.08.26on TipRanks Aug 5 10:05 | +4.2%next day +3.2% · 5 days +5.6% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $4.00 → $3.20−20.0% | Sell | −19.6% | Reiterated | 03.08.26on TipRanks 07:06 | +4.2%next day +3.2% · 5 days +5.6% | ↗ |
| Kyle Boucher★★★★★★★★★★#3152 · hits 100% · avg +25.0% | TD Cowen | $6.00 → $4.00−33.3% | Hold | +0.5% | Assigned | 31.07.26on TipRanks Jul 30 23:17 | −47.5%next day +4.2% · 5 days +10.5% | ↗ |
| Andrew Cooper★★★★★★★★★★#11107 · hits 40% · avg −3.0% | Raymond James | $6.53 → $8.00+22.5% | Buy | +101.0% | Reiterated | 13.01.26on TipRanks 07:31 | −5.4%next day −1.0% · 5 days −4.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Myriad Genetics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $3.05 at a price of $4.31 (−29.2%); now: $3.83 at $3.98 (−3.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 4 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 5 | 4 | 5 | 3 |
| Sell | 1 | 1 | 2 | 2 | 3 | 2 |
Earnings and sales forecast
Next report: 04.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.20 (from $-0.27 to $-0.15). Last quarter: $-0.25.
Sales
Next quarter’s sales estimate — $191M (from $189M to $193M). Last quarter: $191M.
Best top-analyst consensus in the sector · Healthcare
About Myriad Genetics
- CEO: Samraat S. Raha
- Employees: 2,700
- 322 North 2200 West, Salt Lake City, UT, 84116, US
- www.myriad.com
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Data from the stock’s TipRanks forecast page, read 114 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗